叉头框蛋白M1在乳腺癌的进展及治疗耐药中的作用

doi:10.11904/j.issn.1002-3070.2016.05.015

Abstract

Abstract: FoxM1 is a specific transcription factor related to proliferation.Previous studies have found that FoxM1 can enhance the proliferation,metastasis and invasion of cancer cells,and play a crucial role in cancer.Recent studies indicate that the abnormal expression of FoxM1 plays an important role in breast cancer,and its overexpression is negatively correlated with the overall survival of patients.For the early diagnosis of breast cancer,clinical prognosis and study on combination therapy provides a new direction.This article reviews the relationship between FoxM1 and breast cancer.

Key words: FoxM1, Transcription factor, Breast cancer, Therapy

CLC Number:

R737.9

LI Huiying, GENG Jingshu. The role of FoxM1 in the development and treatment of breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 458-462.

References

1 Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.
2 Kalinichenko VV,Major ML,Wang X,et al.Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor[J].Genes Dev,2004,18(7):830-850.
3 Yoshida Y,Wang IC,Yoder HM,et al.The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer[J].Gastroenterology,2007,132(4):1420-1431.
4 Korver W,Roose J,Clevers H.The winged-helix transcription factor trident is expressed in cycling cells[J].Nucleic Acids Res,1997,25(9):1715-1719.
5 Yao KM,Sha M,Lu Z,et al.Molecular analysis of a novel winged helix protein,WIN.Expression pattern,DNA binding property,and alternative splicing within the DNA binding domain[J].J Biol Chem,1997,272(32):19827-19836.
6 Wierstra I,Alves J.FOXM1,a typical proliferation-associated transcription factor[J].Biol Chem,2007,388(12):1257-1274.
7 Lam AK,Ngan AW,Leung MH,et al.FOXM1b,which is present at elevated levels in cancer cells,has a greater transforming potential than FOXM1c[J].Front Oncol,2013,3(11):1-5.
8 Lam EW,Brosens JJ,Gomes AR,et al.Forkhead box proteins:tuning forks for transcriptional harmony[J].Nat Rev Cancer,2013,13(7):482-495.
9 Koo CY,Muir KW,Lam EW.FOXM1:From cancer initiation to progression and treatment[J].Biochim Biophys Acta,2012,1819(1):28-37.
10 Bella L,Zona S,Nestal DMG,et al.FOXM1:A key oncofoetal transcription factor in health and disease[J].Semin Cancer Biol,2014,29:32-39.
11 Luscher-Firzlaff JM,Lilischkis R,Luscher B.Regulation of the transcription factor FOXM1c by Cyclin E/CDK2[J].FEBS Lett,2006,580(7):1716-1722.
12 Wang IC,Chen YJ,Hughes D,et al.Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF(Skp2-Cks1)ubiquitin ligase[J].Mol Cell Biol,2005,25(24):10875-10894.
13 Teh MT,Wong ST,Neill GW,et al.FOXM1 is a downstream target of Gli1 in basal cell carcinomas[J].Cancer Res,2002,62(16):4773-4780.
14 Halasi M,Gartel AL.FOX(M1)news—it is cancer[J].Mol Cancer Ther,2013,12(3):245-254.
15 Green MR,Aya-Bonilla C,Gandhi MK,et al.Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin′s lymphoma[J].Genes Chromosomes Cancer,2011,50(5):313-326.
16 Pandit B,Halasi M,Gartel AL.p53 negatively regulates expression of FoxM1[J].Cell Cycle,2009,8(20):3425-3427.
17 Cancer Genome Atlas Network.Comprehensive molecular portraits of human breast tumours[J].Nature,2012,490(7418):61-70.
18 Ahn H,Sim J,Abdul R,et al.Increased expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor-positive breast cancer[J].J Korean Med Sci,2015,30(4):390-397.
19 Bergamaschi A,Madak-Erdogan Z,Kim YJ,et al.The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells[J].Breast Cancer Res,2014,16(5):436-448.
20 Yang C,Chen H,Tan G,et al.FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer[J].Cancer Lett,2013,340(1):104-112.
21 Xue J,Lin X,Chiu WT,et al.Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-beta-dependent cancer metastasis[J].J Clin Invest,2014,124(2):564-579.
22 Yu G,Zhou A,Xue J,et al.FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway[J].Oncotarget,2015,6(13):11281-11294.
23 Nestal DMG,Delbue D,Silva KL,et al.FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance[J].Cell Signal,2015,27(12):2496-2505.
24 Jackson JG,Kreisberg JI,Koterba AP,et al.Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells[J].Oncogene,2000,19(40):4574-4581.
25 Karadedou CT.Regulation of the FOXM1 transcription factor by the estrogen receptor alpha at the protein level,in breast cancer[J].Hippokratia,2006,10(3):128-132.
26 Madureira PA,Varshochi R,Constantinidou D,et al.The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells[J].J Biol Chem,2006,281(35):25167-25176.
27 Carr JR,Kiefer MM,Park HJ,et al.FoxM1 regulates mammary luminal cell fate[J].Cell Rep,2012,1(6):715-729.
28 Millour J,Constantinidou D,Stavropoulou AV,et al.FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance[J].Oncogene,2010,29(20):2983-2995.
29 Ahn SG,Lee HM,Lee HW,et al.Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score[J].Int J Mol SCI,2013,14(12):23685-23699.
30 Sanders DA,Ross-Innes CS,Beraldi D,et al.Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells[J].Genome Biol,2013,14(1):6-18.
31 Bektas N,Haaf A,Veeck J,et al.Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer[J].BMC Cancer,2008,8:42.
32 Francis RE,Myatt SS,Krol J,et al.FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer[J].Int J Oncol,2009,35(1):57-68.
33 Carr JR,Park HJ,Wang Z,et al.FoxM1 mediates resistance to herceptin and paclitaxel[J].Cancer Res,2010,70(12):5054-5063.
34 Arora R,Yates C,Gary BD,et al.Panepoxydone targets NF-κB and FOXM1 to inhibit proliferation,induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer[J].PLoS One,2014,9(6):e98370.
35 Craig DW,O′Shaughnessy JA,Kiefer JA,et al.Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities[J].Mol Cancer Ther,2013,12(1):104-116.
36 Wang Y,Lee YM,Baitsch L,et al.MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells[J].Elife,2014,3:1763.
37 Wang M,Gartel AL.The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA[J].Oncotarget,2011,2(12):1218-1226.
38 Yang C,Chen H,Yu L,et al.Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer[J].Cancer Gene Ther,2013,20(2):117-124.
39 Kwok JM,Myatt SS,Marson CM,et al.Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression[J].Mol Cancer Ther,2008,7(7):2022-2032.
40 Liu LP,Cao XC,Liu F,et al.Casticin induces breast cancer cell apoptosis by inhibiting the expression of forkhead box protein M1[J].Oncol Lett,2014,7(5):1711-1717.
41 Kwok JM,Peck B,Monteiro LJ,et al.FOXM1 confers acquired cisplatin resistance in breast cancer cells[J].Mol Cancer Res,2010,8(1):24-34.
42 Park YY,Jung SY,Jennings NB,et al.FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair[J].Carcinogenesis,2012,33(10):1843-1853.
43 de Olano N,Koo CY,Monteiro LJ,et al.The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment[J].Mol Cancer Res,2012,10(9):1189-1202.
44 Millour J,de Olano N,Horimoto Y,et al.ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance[J].Mol Cancer Ther,2011,10(6):1046-1058.
45 Khongkow P,Gomes AR,Gong C,et al.Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance[J].Oncogene,2016,35(8):990-1002.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[3]	LI Jiaqi,LUAN Jinwei,ZHANG Yu,LI Xianglan. Analysis of clinicopathological features,recurrence and metastasis in 763 triple-negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 244-249.
[4]	ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.
[5]	LI Shan,ZHAO Chunbo,QIAO Wenbo. Progress in the application of intraoperative radiotherapy in pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 280-283.
[6]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[7]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[8]	LIANG Hong, LI Qi, WANG Yaoxian, JIN Hong, WANG Tong, WANG Yanan, DUAN Yani, SONG Min. Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 134-138.
[9]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[10]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[11]	QIN Lanqun, ZOU Zhengyun. Progress in chemotherapy for malignant melanoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 167-172.
[12]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.
[13]	CHANG Xiaoxia, SONG Bingbing, LIU Jiaren. Research progress in phytochemicals for increasing sensitivity of tumor cells to chemotherapies [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 67-72.
[14]	DING Jiexian, ZHANG Jin, CHEN Yonggang, WANG Xingwen, WANG Shuanke. Progress in Wnt signaling pathway and tumorigenesis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 73-77.
[15]	ZHANG Pan, ZHANG Di, DAI Xiaobo. Advanced in re-radiotherapy for recurrent nasopharyngeal carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 92-96.

The role of FoxM1 in the development and treatment of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments